Nls Pharmaceutics Ag (NLSPW)

概要ニュース株価時系列ディスカッション予測

Nls Pharmaceutics Ag (NLSPW) 最新ニュース

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag (NLSPW) 最新ニュース

NLS Pharmaceutics and Kadimastem eye January merger - Investing.com

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India

NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria

NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India

NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK

NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire

NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan

NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com

NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia

NLS Pharmaceutics sets terms for $1M private placement - Investing.com

NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa

NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com

NLS Pharmaceutics reveals promising preclinical data - Investing.com

NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire

NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire

NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan

NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks

NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com

500: Something went wrong - Investing.com India

Kadimastem Ltd. Faces Financial Uncertainty - TipRanks

NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks

NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance

NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India

NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK

NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire

NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria

NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance

NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire

NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks

NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks

NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com

NLS Pharmaceutics Shareholders Approve Agenda - TipRanks

NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com

NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks

NLSPWに似た銘柄